Keyword: Sanofi

Sanofi is indeed planning to exit Bangladesh, a local executive says, but won't leave local workers or patients high and dry.

Sanofi, which has been testing robots and new production methods, has finally pulled it all together into a near sentient manufacturing operation.

As Sanofi CEO Paul Hudson formulates a new strategy for the company, he visited the U.K. for a headquarters opening ceremony.

Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.

Sanofi plans to employ 350 people at a new shared business site in Budapest, Hungary.

Sanofi CEO Paul Hudson hinted at a coming shakeup—from diabetes to cancer and R&D to marketing. And he's planning to unveil those plans December 10.

Sanofi has been paring away jobs on both sides of the Atlantic for years. Now, it's offering voluntary early retirements to employees in Japan.

Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.

Keytruda-Lenvima combo wins simultaneous OKs. Eisai and Biogen ditch second BACE drug. Sanofi is leaving Bangladesh. Henlius raises $410 million.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.